ClinicalTrials.gg
Status unknownNCT05573503Updated Mar 13, 2023

Effects of a Web Based Education Programme About Sexuality Aimed at Nurses That Care for Patients With Cancer

An interventional study of Bring it up - Assessment and support of patients' sexuality in cancer nursing in Neoplasms, Nurse-Patient Relations and Sexuality, sponsored by Karlstad University. Status unknown at 1 site in Sweden. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-13.

Sponsored by Karlstad University · Not applicable, Interventional, and Health services research

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Enrolling by invitation — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the SexCan - WebEd Nurse study is to evaluate the effect of a five week online university course, "Bring it up - Assessment and support of patients' sexuality in cancer nursing", aimed at cancer nurses, on occupational self-efficacy and attitudes towards addressing sexuality with patients.

Read the detailed description

Cancer nurses attending the course will be recruited. Effects will be used with a pre-post design at two occasions or until we reach 15 participants. Survey data will be collected at baseline and two times post the course. Qualitative interviews with participants will also be performed as well as observational data from the seminars in the course.

The participants' ward managers will also be invited to qualitative interviews considering how to implement the nurses' new knowledge clinically.

02

Conditions studied

  • Neoplasms
  • Nurse-Patient Relations
  • Sexuality

Keywords

  • web based education
  • cancer nurses
03

In context

Neoplasms

9,617 studies on the registry are indexed under Neoplasms; 2,508 are open to participants now.

This study's planned enrollment of 18 is below the median of 50 across 7,432 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Karlstad University is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Registered nurses working as a contact nurses in cancer care who are admitted to the intervention university course.

Exclusion criteria

Exclusion Criteria:

- N/A.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Intervention

    Participants complete baseline assessments and are then assigned the intervention.

    Other: Bring it up - Assessment and support of patients' sexuality in cancer nursing

Interventions

  • OtherBring it up - Assessment and support of patients' sexuality in cancer nursing

    Participants will attend a five week online university course, "Bring it up - Assessment and support of patients' sexuality in cancer nursing". The course addresses theories and models about sexuality in relation to cancer illness, conversation techniques, models for addressing sensitive topics, methods for assessing the impact of cancer on sexuality, methods for preventing and treating sexual problems in relation to cancer, relevant nursing interventions for person-centred counselling about sexuality, and ethical aspects. The teaching consists of literature, online lectures, seminars, clinical practice, and written exams. A university certificate will be issued to participants who pass all exams.

06

What researchers measure

Primary outcomes

  1. Change in Occupational Self-Efficacy (from baseline to 5 weeks post finished intervention)

    Measured with the "Short Occupational Self-Efficacy Scale". This instrument ranges from 6 to 36 points, where higher values indicate a higher grade of self-efficacy.

    Time frame: At baseline and then 5 weeks post finished intervention.

  2. Change in Occupational Self-Efficacy (from baseline to 19 weeks post finished intervention)

    Measured with the "Short Occupational Self-Efficacy Scale"

    Time frame: At baseline and then 19 weeks post finished intervention.

  3. Change in Attitudes towards addressing sexuality (from baseline to 5 weeks post finished intervention)

    Measured with the "Sexual Health - Extended Version - Swedish (PASH-Ext-S)". The instrument ranges from 27 to 135 points. Higher values indicate a higher degree of positive attitudes to addressing sexuality.

    Time frame: At baseline and then 5 weeks post finished intervention.

  4. Change in Attitudes towards addressing sexuality (from baseline to 19 weeks post finished intervention)

    Measured with the "Sexual Health - Extended Version - Swedish (PASH-Ext-S)"

    Time frame: At baseline and then 19 weeks post finished intervention.

Secondary outcomes

  1. Change in Knowledge about the influence of cancer on sexuality (from baseline to 5 weeks post finished intervention)

    Study specific questionnaire

    Time frame: At baseline and then 5 post finished intervention.

  2. Change in Knowledge about the influence of cancer on sexuality (from baseline to 19 weeks post finished intervention)

    Study specific questionnaire

    Time frame: At baseline and then 19 weeks post finished intervention.

  3. Change in Number of conversations with patients relating to sexuality (from baseline to 5 weeks post finished intervention)

    Time frame: At baseline and then 5 weeks post finished intervention.

  4. Change in Number of conversations with patients relating to sexuality (from baseline to 5 weeks post finished intervention)

    Time frame: At baseline and then 19 weeks post finished intervention.

07

Study locations

1 site
  • Karlstad University
    Karlstad, Värmland County 65188, Sweden
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Mar 2024, 17 months after the start.

Of 1,358 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 71. This study's planned 17 months is below that.

Counting every sponsor, half of 1,404 studies reached it within 38 months; a quarter within 17 and three quarters within 71.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2022
First posted
Oct 10, 2022
StartActual
Oct 14, 2022
Primary completionEst.
Mar 31, 2024
CompletionEst.
Mar 31, 2024
Last update
Mar 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05573503
Lead sponsor
Karlstad University
Responsible party
Cecilia Olsson (PhD, Senior lecturer, associate professor, Karlstad University) — Principal investigator
First posted
Oct 10, 2022
Start date
Oct 14, 2022
Primary completion
Mar 31, 2024 (estimated)
Completion
Mar 31, 2024 (estimated)
Last update
Mar 13, 2023

Study contacts

Cecilia Olsson, PhD
principal investigator · Karlstad University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion